Fapon Presents AI-Driven Diagnostic Innovation and Advanced Alzheimer's Disease Blood Testing Solutions

Fapon, a global leader in life sciences, is participating at MEDICA 2025 from November 17 to 20 in Düsseldorf, Germany, where it is underscoring its strengths in diagnostic innovation. At booth A81 in Hall 3, the company is presenting how AI-driven technologies are advancing diagnostic R&D and unveiling a range of IVD solutions and new products, with particular emphasis on its state-of-the-art blood testing solutions for Alzheimer’s disease (AD).

Fapon’s “AI-driven + closed-loop dry and wet experimentation” R&D model greatly enhances the efficiency of biomarker discovery and the development of diagnostic solutions. A standout achievement of this approach is the company’s advanced AD blood testing solution. Designed to support IVD manufacturers, it offers a complete suite of raw materials and bulk reagents for core Alzheimer’s biomarkers, including p-tau 217, p-tau 181, amyloid beta 40, amyloid beta 42, GFAP, NfL, and APOE4. These innovative materials deliver high sensitivity and specificity, with strong concordance to predicate kits and established clinical tests, enabling the development of more precise and reliable AD assays.

Image: Fapon is exhibitng at Booth #3A81 in MEDICA 2025 (Photo courtesy of Fapon Biotech)

Fapon is also presenting its full suite of one-stop IVD solutions, encompassing raw materials, reagent development services, and open-platform instruments. A highlight is the chemiluminescence one-stop solution, which integrates high-performance core materials, a panel of more than 70 self-developed assays, and the versatile Shine i-Series CLIA analyzers encompassing low to ultra-high throughput to address testing demands across diverse clinical settings. Additionally, the Shine mT8000 Fully Automatic Clinical Chemistry and Immunoassay System provides end-to-end workflow automation within a compact, space-efficient footprint of just 5 m².

Fapon is also showcasing its portfolio of high-performance IVD raw materials, including recombinant quality-control and calibrator components for key disease markers such as RF, HbA1c, HIV/HIV-P24, HCV, TP, HBV, and ToRCH. The company is further highlighting its animal-origin-free IgG blockers and LAMP solutions designed for rapid molecular testing.

Related Links:
Fapon Biotech